Sponsors / RXRX
RXRX

Recursion Pharmaceuticals Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
4Trials in this database
13Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
The Symptomatic Cerebral Cavernous Malformation Trial of REC-994NCT05085561RXRXPhase 2Completed2025-06-30Actual
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated MeningiomasNCT05130866RXRXPhase 2, Phase 3Terminated2025-08-18Actual
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC MutationNCT06005974RXRXPhase 2Terminated2025-02-24Actual
The Clostridioides Difficile Trial of REC-3964NCT06536465RXRXPhase 2Terminated2025-05-06Actual

Latest recorded trial changes

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

NCT06005974 · Recursion Pharmaceuticals Inc.

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: To evaluate the safety and tolerability of REC-4881 Measure: To evaluate the preliminary anti-tumor activity of REC-4881 as measured by Objective Response Rate (ORR)

+ After

Measure: Number of Participants with Dose Limiting Toxicities Measure: Objective Response Rate

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

60 participants (planned)

+ After

18 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Jan 2027

+ After

24 Feb 2025

Recruitment status changed

− Before

Active not recruiting

+ After

Terminated

Check registry source
The Clostridioides Difficile Trial of REC-3964

NCT06536465 · Recursion Pharmaceuticals Inc.

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Number of Participants with Survival Without Recurrence or Requirement for Additional CDI Treatment Measure: Number of Participants with Treatment-emergent Adverse Events (TEAEs) Measure: Number of Participants with Related TEAEs Measure: Number of Participants with Serious TEAEs Measure: Number of Participants with TEAEs Leading to Study Drug Discontinuation

+ After

Measure: Number of Participants With Survival Without Recurrence or Requirement for Additional Clostridioides Difficile Infection (CDI) Treatment Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Measure: Number of Participants With Related TEAEs Measure: Number of Participants With Serious TEAEs Measure: Number of Participants With TEAEs Leading to Study Drug Discontinuation

Check registry source
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

NCT05130866 · Recursion Pharmaceuticals Inc.

· 6 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Progression-free survival (PFS) in Cohort A Measure: Progression-free survival (PFS) in Cohort B

+ After

Measure: Cohort A: Number of Participants with Progression-free survival (PFS) at 6 Months Measure: Cohort B: Number of Participants with PFS up to 3 years

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

92 participants (planned)

+ After

25 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Jan 2027

+ After

18 Aug 2025

Recruitment status changed

− Before

Recruiting

+ After

Terminated

Check registry source